Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the updraftplus domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wprss domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wprss domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114
Dow Jones Newswires: Nevro to pay Boston Scientific $20 million in patent infringement case – Vested Daily

Dow Jones Newswires: Nevro to pay Boston Scientific $20 million in patent infringement case

Nevro Corp. is expected to pay $20 million to Boston Scientific Corp. after a Delaware jury found that the medical device company had infringed on two Boston Scientific patents related to the manufacturing of a spinal cord stimulation technology, the company said late Monday.

The jury found that Nevro infringed on two lead patents involving the ways spinal cord stimulation technology were manufactured. The manufacturing methods were implemented by a third-party supplier, Nevro
NVRO,
+2.22%

said. Two other Boston Scientific
BSX,
-0.77%

patents weren’t infringed.

“We disagree with the finding by the jury and plan to appeal,” Nevro General Counsel Kashif Rashid said in a release.

The jury’s decision doesn’t have any commercial implications or place any restrictions on current or future Nevro products, the Redwood City, Calif., company said. The amount of money that will be awarded to Boston Scientific won’t have a material effect on its business, Nevro said.

“We are gratified that the jury upheld Boston Scientific spinal cord stimulation lead patents and recognized that Nevro should pay for infringing those patents,” a Boston Scientific spokeswoman said in an emailed statement.

This post was originally published on Market Watch

Financial News

Daily News on Investing, Personal Finance, Markets, and more!